Predictive Factors Associated to Bile Cultures and Antibiogram Resistance in Patients with Laparoscopic Cholecystectomy (BACILO)

March 14, 2025 updated by: Camilo Ramirez Giraldo, Hospital Universitario Mayor Méderi

Predictive Factors Associated with Bile Culture Positivity and PhenotypiCal AntIbiogram Resistance Patterns in Patients Taken to LaparOscopic Cholecystectomy (BACILO): a Protocol for a Prediction Model Study

The BACILO study was designed with the objective of having robust data on local epidemiological bacterial colonisation information on bile cultures with patients taken to laparoscopic cholecystectomy in our institution to find which predictive factors are associated with culture positivity and antibiotic resistance patterns. Secondary endpoints include evaluating demographical, clinical and surgical variables and establishing comparison between both positive and negative bile cultures and between antibiotic sensitive and resistant microorganism strain isolations.

Study Overview

Detailed Description

BACILO is single-centre, observational, analytical, prospective study with a prognostic prediction model with the objective of identifying predictive factors associated with microbial and antibiotic resistance patterns in bile cultures of patients taken to laparoscopic cholecystectomy in our institution. Primary outcomes are bile culture positivity and phenotypical resistance antibiogram patterns while secondary outcomes include demographic, clinical and surgical characteristics and surgical outcomes. The main objective is to determine predictive factors using a prediction model, variables included are: Age, diabetes mellitus, C-reactive protein test, choledocholithiasis/ERCP, cholecystitis and severity of cholecystitis according to the 2018 Tokyo guidelines.This in the nature of describing the relationship between bile culture positivity and phenotypical antibiogram resistance patterns in our institution, and establish thus better treatment strategies based on higher quality local evidence.

Study Type

Observational

Enrollment (Actual)

703

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Cundinamarca
      • Bogota, Cundinamarca, Colombia, 111221
        • Hospital Universitario Mayor-Méderi
      • Bogota, Cundinamarca, Colombia, 111221
        • Hospital Universitario Méderi Barrios Unidos

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients that are over 18 years that have an indication for laparoscopic cholecystectomy in our institution without any of the exclusion criteria, which had bile cultures taken from the surgical specimen (gallbladder) during the surgery and attended the postoperative15 day follow-up appointment after hospital discharge.

Description

Inclusion Criteria:

  • Patients included must be over 18 years of age and be taken to laparoscopic cholecystectomy between March 2024 and February 2026 in any institution of the Méderi hospital network (Hospital Universitario Mayor and Hospital Universitario Barrios Unidos), have signed the written informed consent to be included in the study and have both bile culture and antibiogram.

Exclusion Criteria:

  • - Patients that will be taken to laparoscopic cholecystectomy with another concomitant surgical procedure (including but not exclusive to gastrectomy, pancreatoduodenectomy, oesophagectomy, splenectomy, abdominal wall reconstruction, colectomy, amongst others) with the exception of umbilical herniorrhaphy.
  • Patients without a postoperative control appointment.
  • Patients with an untreated HIV diagnosis.
  • Patients with diagnosis of a malignant gallbladder or biliary tract disease documented preoperatively.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Bile culture positivity
Time Frame: Perioperatively, during the procedure and immediately after the intervention
Bile culture is tested positive for at least one (1) microorganism
Perioperatively, during the procedure and immediately after the intervention
Phenotypical antibiogram resistance
Time Frame: Perioperatively, during the procedure and immediately after the intervention
If bile culture is positive, evaluation for possible antibiotic resistance vs sensitivity
Perioperatively, during the procedure and immediately after the intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Microbial characteristics
Time Frame: Immediately after the intervention
To describe the microbial characteristics of the bile cultures and their phenotypical antibiogram resistance
Immediately after the intervention
Bile culture and antibiotic resistance relationship
Time Frame: Immediately after the intervention
Explore the relationship between positive bile cultures and phenotypical antibiogram resistance with surgical outcomes
Immediately after the intervention
Demographical and clinical characteristics
Time Frame: Pre-intervention
To describe and compare the demographic and clinical characteristics of the study population.
Pre-intervention
Surgical characteristics and outcomes
Time Frame: During the 15 day postoperative follow-up appointment
To describe and compare the surgical characteristics and outcomes of the study population
During the 15 day postoperative follow-up appointment
Determination of predictive factors (age, diabetes mellitus, choledocholithiasis / ERCP, C-reactive protein, cholecystitis and Tokyo guidelines severity of cholecystitis)
Time Frame: Through study completion, around 1 year and a half
To determine demographic and clinical predictive factors for positive bile cultures and phenotypical antibiogram resistance.
Through study completion, around 1 year and a half

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2024

Primary Completion (Actual)

October 26, 2024

Study Completion (Actual)

December 24, 2024

Study Registration Dates

First Submitted

March 8, 2024

First Submitted That Met QC Criteria

March 13, 2024

First Posted (Actual)

March 18, 2024

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

March 14, 2025

Last Verified

March 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2023-18
  • DVO005 2555-CV1837 (Other Identifier: Universidad del Rosario Research Ethics Committee)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Data obtained and input into the database is anonymous, without any individual or identifying characteristics will be stored in a dataset from the Centro de Recursos para el Aprendizaje y la Investigación, property of and administered by the Universidad del Rosario as a plan of data management. Moreover, the different codes used in the analysis will be stored in this dataset.

IPD Sharing Time Frame

It is in our plans once we obtain a register number from Clinical Trials in order to publish the protocol, statistical analysis plan and clinical study report in a scientific journal so it will be available to all people interested.

IPD Sharing Access Criteria

It is in our plans to be published in a scientific journal available to all people interested.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Antibiotic Resistant Strain

Clinical Trials on Bile culture and phenotypic antibiogram resistance test

Subscribe